Biotechnology is becoming a decisive capability for Europe’s competitiveness, industrial resilience and strategic autonomy. But Europe enters the next institutional cycle with a fragmented policy landscape, uneven regulatory capacity, and persistent scale-up barriers. The Commission’s Biotech Communication I and Biotech Communication II set out an initial toolbox, but fall short of an end-to-end industrial framework comparable to the US. The gap between ambition and execution remains significant. To what extent do these communications address the core challenges of Europe’s biotech sector? Where are the structural gaps that still block growth and industrial deployment?
#PMBiotech
Interested in this event?
Share This Event
